Worth Reading

What we are reading, and why.

Articles, guidance, and commentary from regulators, industry, and other experts that we think are worth your time. The subjects range as widely as our work does, from new regulations and modalities to process change, automation, and AI.

Worth Reading

11-06-2026

FDA Warning Letter highlights risks of using AI in drug manufacturing

An April 2026 warning letter for cGMP documents generated by AI agents without Quality Unit review: the failure that human-in-the-lead governance prevents.
11-05-2026

GxP Inspection-Ready AI Tools: Building Risk-Based QA Frameworks for AI/ML in GxP Operations

Six steps from intended use to change control and monitoring. "An AI system that cannot be governed should not be used for GxP purposes."
11-04-2026

EMA adopts reflection paper on AI/ML in drug development

How Europe frames AI across the whole medicinal product lifecycle, manufacturing and pharmacovigilance included: risk-based, with "high regulatory impact" and "high patient risk" aligned to the EU AI Act.
11-03-2026

Use of AI for GXP inspection responses: setting standards without stifling innovation

The MHRA Inspectorate on AI-drafted responses with invented references, and why every response needs experienced review and an accountable signature.
11-02-2026

FDA Warning Letter to ABS Corporation, 23 July 2026

Out-of-specification results averaged away, an in-process limit overwritten to fit the data, and batches released anyway. Specifications are not negotiable, and the evidence shows when they were.
08-24-2026

Looking at Innovation Under QMSR

How a device company can build a development system that absorbs change without losing discipline, now that FDA's QMSR expects risk management and regulatory planning across the whole product lifecycle.